Literature DB >> 25677350

HLA-B alleles B*15:01 and B*15:02: opposite association with hepatitis C virus infection in Chinese voluntary blood donors.

Huaping Xiong1, Jieting Huang, Xia Rong, Ming Zhang, Ke Huang, Ru Xu, Min Wang, Chengyao Li, Qiao Liao, Wenjie Xia, Guangping Luo, Xin Ye, Ling Lu, Yongshui Fu, Tai Guo, Kenrad Nelson.   

Abstract

BACKGROUND: Although human leukocyte antigens (HLA) have been shown in association with the outcomes of hepatitis C virus (HCV) infection among different ethnic groups, such studies remain absent in China, where the HCV prevalence is higher than the global average.
METHODS: In this study, 426 HCV-infected and 709 uninfected blood donors were analyzed, among whom the HLA alleles were sequenced using a high-resolution genotyping method.
RESULTS: At the 2-digit level, none of the alleles showed a statistical difference between the HCV-infected and uninfected groups. However, at the 4-digit level, the HLA-B alleles B*15:01 and B*15:02 showed an opposite association with HCV infection, i.e. B*15:01 was significantly higher in the HCV-infected group (odds ratio, OR = 1.561, p = 0.010), while B*15:02 was significantly higher in the uninfected group (OR = 0.778, p = 0.016). We also identified a higher frequency of B*13:02 in the HCV-infected group (OR = 1.515, p = 0.009) and a higher frequency of B*07:05 in the uninfected group (OR = 0.299, p = 0.001).
CONCLUSIONS: The frequencies of four HLA alleles, B*07:05, B*13:02, B*15:01, and B*15:02, were found to be significantly different between the HCV-infected and uninfected blood donors in China, revealing an inverse relation of B*15:01 and B*15:02 with HCV infection. This finding suggests that the ethnic genetic variations of HLA may greatly affect the host immune responses against HCV.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25677350      PMCID: PMC4394015          DOI: 10.1159/000369209

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  33 in total

1.  The importance of assessing effect modification when asserting racial differences in associations between human leukocyte antigen class II alleles and hepatitis C virus outcomes.

Authors:  Olga L Sarmiento; Chandra L Ford; Elizabeth C Newbern; William C Miller; Charles Poole; Jay S Kaufman
Journal:  J Infect Dis       Date:  2002-01-15       Impact factor: 5.226

2.  Control of confounding of genetic associations in stratified populations.

Authors:  Clive J Hoggart; Eteban J Parra; Mark D Shriver; Carolina Bonilla; Rick A Kittles; David G Clayton; Paul M McKeigue
Journal:  Am J Hum Genet       Date:  2003-06       Impact factor: 11.025

Review 3.  T cells and viral persistence: lessons from diverse infections.

Authors:  Paul Klenerman; Ann Hill
Journal:  Nat Immunol       Date:  2005-09       Impact factor: 25.606

4.  Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Authors:  Photini Kiepiela; Alasdair J Leslie; Isobella Honeyborne; Danni Ramduth; Christina Thobakgale; Senica Chetty; Prinisha Rathnavalu; Corey Moore; Katja J Pfafferott; Louise Hilton; Peter Zimbwa; Sarah Moore; Todd Allen; Christian Brander; Marylyn M Addo; Marcus Altfeld; Ian James; Simon Mallal; Michael Bunce; Linda D Barber; James Szinger; Cheryl Day; Paul Klenerman; James Mullins; Bette Korber; Hoosen M Coovadia; Bruce D Walker; Philip J R Goulder
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

5.  HLA-Cw*04 and hepatitis C virus persistence.

Authors:  Chloe L Thio; Xiaojiang Gao; James J Goedert; David Vlahov; Kenrad E Nelson; Margaret W Hilgartner; Stephen J O'Brien; Peter Karacki; Jacquie Astemborski; Mary Carrington; David L Thomas
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 6.  Host genetic determinants in hepatitis C virus infection.

Authors:  L J Yee
Journal:  Genes Immun       Date:  2004-06       Impact factor: 2.676

7.  Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.

Authors:  Jianming Tang; Shenghui Tang; Elena Lobashevsky; Angela D Myracle; Ulgen Fideli; Grace Aldrovandi; Susan Allen; Rosemary Musonda; Richard A Kaslow
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source.

Authors:  Susan M McKiernan; Richard Hagan; Michael Curry; George S A McDonald; Alan Kelly; Niamh Nolan; Anne Walsh; John Hegarty; Emer Lawlor; Dermot Kelleher
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

Review 10.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

View more
  3 in total

1.  The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population.

Authors:  Jieting Huang; Ke Huang; Ru Xu; Min Wang; Qiao Liao; Huaping Xiong; Chengyao Li; Xi Tang; Zhengang Shan; Ming Zhang; Xia Rong; Kenrad Nelson; Yongshui Fu
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

Review 2.  Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?

Authors:  Nicole B Crux; Shokrollah Elahi
Journal:  Front Immunol       Date:  2017-07-18       Impact factor: 7.561

3.  HLA-B*15 predicts survival in Egyptian patients with COVID-19.

Authors:  Ahmed Samir Abdelhafiz; Asmaa Ali; Merhan A Fouda; Douaa M Sayed; Mahmoud M Kamel; Lamyaa Mohamed Kamal; Mahmoud Ali Khalil; Rania M Bakry
Journal:  Hum Immunol       Date:  2021-09-27       Impact factor: 2.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.